{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-03T17:09:36.655556+00:00","company":{"ticker":"GKOS","cik":1192448,"company_name":"GLAUKOS Corp"},"pagination":{"limit":100,"returned":2,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","facts":[{"fact_type":"earnings_release","fact_key":"6131ca75c4b27ea1cee0d9b01868d7d435c581fe","cik":1192448,"ticker":"GKOS","company_name":"GLAUKOS Corp","filed_at":"2026-04-29T23:59:59+00:00","payload":{"eps_text":"($0.34) per diluted share","guidance_signal":"raised","item_codes_triggered":["2.02"],"net_income_text":"$19.8 million","period_text":"the first quarter ended March 31, 2026","report_date":"2026-04-29","result_type":"reported_results","revenue_text":"$150.6 million"},"claim":"GLAUKOS Corp reported the first quarter ended March 31, 2026 results: revenue $150.6 million, net income $19.8 million, EPS ($0.34) per diluted share. Guidance raised.","evidence_excerpt":"of glaucoma, corneal disorders, and retinal diseases, today announced financial results for the first quarter ended March 31, 2026. Key highlights include: • Record net sales of $150.6 million in Q1 2026 increased 41% year-over-year on a reported basis and 39% year-over-year on a constant currency basis. • Glaucoma record net sales of $129.3 million in Q1 2026","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-26-191553","anchor_url":"https://secwatch.observer/filing/0001193125-26-191553#claim-6131ca75c4b27ea1cee0d9b01868d7d435c581fe","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1192448/000119312526191553/0001193125-26-191553-index.htm"},{"fact_type":"earnings_release","fact_key":"c6d75046738a7059c6537ecfe463a084c578794b","cik":1192448,"ticker":"GKOS","company_name":"GLAUKOS Corp","filed_at":"2024-05-01T23:59:59+00:00","payload":{"eps_text":"($0.82) per diluted share","guidance_signal":"raised","item_codes_triggered":["2.02"],"net_income_text":"($40.8 million)","period_text":"first quarter ended March 31, 2024","report_date":"2024-05-01","result_type":"reported_results","revenue_text":"$85.6 million"},"claim":"GLAUKOS Corp reported first quarter ended March 31, 2024 results: revenue $85.6 million, net income ($40.8 million), EPS ($0.82) per diluted share. Guidance raised.","evidence_excerpt":"of glaucoma, corneal disorders and retinal diseases, today announced financial results for the first quarter ended March 31, 2024. Key highlights include: ● Record net sales of $85.6 million in Q1 2024 increased 16% year-over-year. ● Glaucoma record net sales of $67.2 million in Q1 2024 increased 20% year-over-year. ● Corneal Health net sales of $18.4 million in Q1","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001558370-24-006383","anchor_url":"https://secwatch.observer/filing/0001558370-24-006383#claim-c6d75046738a7059c6537ecfe463a084c578794b","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1192448/000155837024006383/0001558370-24-006383-index.htm"}]}